Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-resistant Schizophrenia Clear all
Completed Phase 4 Interventional Results available

Minocycline Augmentation to Clozapine

NCT02124811
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Minocycline
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

NCT01569659
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness

NCT03935854
View directory record Official record
Conditions
Obesity, Ketogenic Dieting, Metabolic Syndrome, Bipolar Disorder, Schizophrenia, Weight Gain, Psychotropic Agents Causing Adverse Effects in Therapeutic Use, Brain Metabolic Disorder
Interventions
LCHF, Ketogenic Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

Salsalate for Insulin Resistance in Schizophrenia

NCT01182727
View directory record Official record
Conditions
Schizophrenia, Insulin Resistance
Interventions
salsalate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 17, 2026, 5:07 AM EDT
Terminated Not applicable Interventional Results available

Treating Refractory Schizophrenia With rTMS

NCT02242578
View directory record Official record
Conditions
Schizophrenia
Interventions
1 Hz rTMS, 10 Hz rTMS
Device
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 17, 2026, 5:07 AM EDT
Suspended Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia

NCT05259306
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Insightec Exablate Neuro MR-guided focused ultrasound transducer
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Phase 4 Interventional

Treating Drug-Resistant Childhood Schizophrenia

NCT00048828
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
3
States / cities
Dix Hills, New York • Glen Oaks, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 17, 2026, 5:07 AM EDT
Not yet recruiting Not applicable Interventional

Deep Brain Stimulation for Treatment-Resistant Schizophrenia

NCT07592611
View directory record Official record
Conditions
Treatment Resistant Disorders
Interventions
Medtronic Percept with SensSight Deep Brain Stimulation System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 5:07 AM EDT
Active, not recruiting Phase 2 Interventional

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

NCT05838560
View directory record Official record
Conditions
Schizophrenia, Treatment Resistant Depression, Aging, Premature
Interventions
Dasatinib, quercetin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 17, 2026, 5:07 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Lu AF35700, Risperidone, Olanzapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 17, 2026, 5:07 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Phase 2Phase 3 Interventional

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Treatment of Refractory Schizophrenia With Riluzole

NCT00375050
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 17, 2026, 5:07 AM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

NCT06748950
View directory record Official record
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 17, 2026, 5:07 AM EDT
Completed No phase listed Observational

FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

NCT00683891
View directory record Official record
Conditions
Weight Gain, Sialorrhea
Interventions
FazaClo (clozapine, USP) ODT
Drug
Lead sponsor
Azur Pharma, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Costa Mesa, California • Gastonia, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Sep 17, 2026, 5:07 AM EDT
Completed No phase listed Observational

Neural Biomarkers of Clozapine Response

NCT03076346
View directory record Official record
Conditions
Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Phase 4 Interventional

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

NCT00287820
View directory record Official record
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Sep 17, 2026, 5:07 AM EDT
Terminated Not applicable Interventional

Deep Brain Stimulation in Treatment Resistant Schizophrenia

NCT02361554
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Medtronic Percept with SensSight Deep Brain Stimulation System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia

NCT00552500
View directory record Official record
Conditions
Insulin Resistance, Body Composition
Interventions
Depakote (valproate)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

NCT00539071
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training

NCT00431223
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation therapy
Behavioral
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

NCT02717195
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine, Lu AF35700
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Bellflower, California • Cerritos, California • Costa Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 17, 2026, 5:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Electroconvulsive Therapy in Clozapine Refractory Schizophrenia

NCT00042224
View directory record Official record
Conditions
Schizophrenia
Interventions
Electroconvulsive Therapy (ECT), Clozapine
Procedure · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 17, 2026, 5:07 AM EDT